Abstract
Recently, microRNAs (miRNAs) are emerging as new regulators in the pathogenesis of temporal lobe epilepsy (TLE) and playing a major role in the inflammatory and immune processes. The aim of the present study was to evaluate the dynamic expression of brain-specific miR-183 and miR-135a, brain-enriched miR-125b and miR-128 and inflammation-related miR-30c and miR-27a. Status epilepticus evoked by pilocarpine administeration was used to induce epilepsy in rats. Quantitative polymerase chain reaction was performed on rat hippocampus 2 hours, 3 weeks and 2 months following pilocarpine-induced status epilepticus, representing the acute, latent, and chronic phases, respectively. Expression levels were also measured in hippocampus obtained from TLE patients and normal controls. In the rat model, miR-183, miR-135a and miR-125b were detected upregulated during the acute and chronic phases compared to controls, but not during the latent phase. miR-30c and miR-27a were upregulated in the acute and chronic phases of TLE, while in the latent phase miR-30c was downregulated and miR-27a was upregulated. On the other hand, miR-128 showed significantly downregulated in all phases of TLE development. In TLE patients, miR-183, miR- 135a, miR-125b, miR-30c and miR-27a were upregulated, whereas miR-128 was downregulated. Our study revealed upregulation of miR-183, miR-135a and miR-125b in the seizure-related phases and TLE patients, suggesting that all may provide a potential therapeutic approach for the treatment of TLE, whereas the dysregulation of miR-128, miR-30c and miR-27a may suggest different functions during the process of TLE development.
Keywords: Hippocampus, inflammation, microRNAs, status epilepticus, temporal lobe epilepsy.
CNS & Neurological Disorders - Drug Targets
Title:Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
Volume: 14 Issue: 8
Author(s): Walid Alsharafi and Bo Xiao
Affiliation:
Keywords: Hippocampus, inflammation, microRNAs, status epilepticus, temporal lobe epilepsy.
Abstract: Recently, microRNAs (miRNAs) are emerging as new regulators in the pathogenesis of temporal lobe epilepsy (TLE) and playing a major role in the inflammatory and immune processes. The aim of the present study was to evaluate the dynamic expression of brain-specific miR-183 and miR-135a, brain-enriched miR-125b and miR-128 and inflammation-related miR-30c and miR-27a. Status epilepticus evoked by pilocarpine administeration was used to induce epilepsy in rats. Quantitative polymerase chain reaction was performed on rat hippocampus 2 hours, 3 weeks and 2 months following pilocarpine-induced status epilepticus, representing the acute, latent, and chronic phases, respectively. Expression levels were also measured in hippocampus obtained from TLE patients and normal controls. In the rat model, miR-183, miR-135a and miR-125b were detected upregulated during the acute and chronic phases compared to controls, but not during the latent phase. miR-30c and miR-27a were upregulated in the acute and chronic phases of TLE, while in the latent phase miR-30c was downregulated and miR-27a was upregulated. On the other hand, miR-128 showed significantly downregulated in all phases of TLE development. In TLE patients, miR-183, miR- 135a, miR-125b, miR-30c and miR-27a were upregulated, whereas miR-128 was downregulated. Our study revealed upregulation of miR-183, miR-135a and miR-125b in the seizure-related phases and TLE patients, suggesting that all may provide a potential therapeutic approach for the treatment of TLE, whereas the dysregulation of miR-128, miR-30c and miR-27a may suggest different functions during the process of TLE development.
Export Options
About this article
Cite this article as:
Alsharafi Walid and Xiao Bo, Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients, CNS & Neurological Disorders - Drug Targets 2015; 14 (8) . https://dx.doi.org/10.2174/1871527314666150317225945
DOI https://dx.doi.org/10.2174/1871527314666150317225945 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Novel Treatments in Subarachnoid Hemorrhage
The current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Developments of Thalidomide Derivatives Possessing Anti-Inflammatory Activity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Rationale Design, Synthesis, and Pharmacological Evaluation of Isatin Analogues as Antiseizure Agents
Letters in Drug Design & Discovery Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases
Current Topics in Medicinal Chemistry Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Restless Legs Syndrome in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Assessing Glutamatergic Function and Dysfunction in Peripheral Tissues
Current Medicinal Chemistry “Micromanaging” Glioblastoma Multiforme: The Potential of MicroRNAs, Circular RNAs, and the Hippo Pathway as Novel Treatment Strategies
Current Neurovascular Research Ivabradine: The Hope for a Good Treatment of Ischemic Heart Disease
Current Medicinal Chemistry Targeting γ-Aminobutyric Acid (GABA) Carriers to the Brain: Potential Relevance as Antiepileptic Pro-Drugs
Medicinal Chemistry Adenosine Receptor Ligands-Recent Developments Part I. Agonists
Current Medicinal Chemistry Chemistry and Biology of Thyrotropin-Releasing Hormone (TRH) and its Analogs
Current Medicinal Chemistry Selection and Evaluation of the Pediatric Epilepsy Surgical Candidates
Current Pediatric Reviews Improving Cognitive Outcome in Cerebral Malaria: Insights from Clinical and Experimental Research
Central Nervous System Agents in Medicinal Chemistry Antiepileptic Treatment Strategy in Vascular Malformations
Current Pharmaceutical Design Immunogenic Issues Concerning Recombinant Adeno-Associated Virus Vectors for Gene Therapy
Current Gene Therapy Antioxidants as a Preventive Treatment for Epileptic Process: A Review of the Current Status
Current Neuropharmacology Subject Index to Volume 3
Current Drug Targets - CNS & Neurological Disorders The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants
Current Drug Metabolism GABA Transporters and GABA-Transaminase as Drug Targets
Current Drug Targets - CNS & Neurological Disorders